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life? What percentage of patients requires repetitive imaging scans
and further irradiation, and at what risk? What is the morbidity
and mortality attendant to the biopsies and surgery for lesions that
ultimately turn out to be benign?
I believe we are at a crossroads where additional input from
epidemiologists, oncologists, radiologists, cardiologists, and others
is required to delineate further how far to widen or restrict the
MDCT “field of view.” Because large randomized prospective
studies are unlikely in this regard, perhaps mathematical models of
outcomes and costs could be formulated.
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Reply
Dr. Fleet raises important questions, and there is legitimate
concern that computed tomography (CT) scan “incidentalomas”
can result in unnecessary or inappropriate testing at the expense of
the insurance system and/or risk to the patient (1,2).
The main issue regarding cardiac CT is, of course, coincident
imaging of the adjacent lungs. Although lung cancer is the number
one cause of cancer-related deaths in all men and women in
America, the finding of variable size “lung nodules” is much more
common than true malignant disease. Dr. Fleet asks: “When
found, are the newly discovered malignancies curable or amenable
to treatment that prolongs life or improves quality of life?” We may
never have a complete answer to this inquiry. However, the overall
survival rates for lung cancer are dismal, and the most recent report
from the ELCAP (Early Lung Cancer Action Program) study (3)
may provide a partial response. Henschke and colleagues (3) did
screening lung scans in adults over 40 years old with either a
history of cigarette smoking, an occupational exposure risk, or
significant exposure to second-hand smoke, and they found that
stage I lung cancers discovered (and treated) resulted in a projected
80% 10-year survival. These subjects are, coincidentally, at greatest
risk for atherosclerotic heart disease. Importantly, however, lung
cancer was found in only 484 (1.5%) of 31,567 screened individuals.
Dr. Fleet asks, “What is the morbidity and mortality attendant
to the biopsies and surgery for lesions that ultimately turn out to be
benign?” This is a rhetorical question as we do not have this
information; however, in most instances biopsies are unnecessary,
and follow-up low-dose CT scanning may be the only suggested
consequence. In medicine we tend to “pass the buck” when it
comes to test results that are unanticipated, and the best way to
reduce unnecessary follow-up testing or procedures is physician
education. There are guidelines published by the ELCAP inves-
tigators (4), which prescribe follow-up on the basis of lung nodule
dimensions. More recently the Fleischner Society (5) described the
workup of small pulmonary nodules incorporating smoking history
as part of the clinical algorithm.
I agree that we are at a crossroad to define the clinical impact of
diagnostic CT angiography and “extravascular” pathology, regard-
less of whether it involves the heart/chest, neck, abdomen, or
periphery. The issue clearly extends beyond traditional single-
specialty medicine. Recently, a published commentary (6) ad-
dressed training in advanced cardiovascular imaging, stating that
“specific interpretation of the extra-cardiac fields should be per-
formed. . . . Regarding the cardiovascular medicine specialist per-
forming a cardiac CT, the American College of Cardiology
recognizes and endorses education and training of such individuals
in the recognition of incidental scan findings in support of quality
imaging care of patients with cardiovascular disease. . . . To this
end, it is felt that Level 2 and Level 3 training should include
review of all cardiac CT for noncardiac findings.”
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Reply
We thank Dr. Fleet for his interest in our study (1) and appreciate
his comments. We agree with Dr. Fleet as to the necessity of
further evidence to establish the clinical significance of noncardiac
analysis in cardiac multidetector computed tomography (MDCT).
Our study lacks long-term clinical follow-up to discuss clinical
outcomes. In addition, we did not discuss cost because the actual
cost of additional follow-up, including surgery, biopsy, and imag-
ing, varies among countries and institutions. As clinical results and
costs could be different depending on how referring physicians
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respond to the reports, a mathematical analysis regarding outcomes
and cost might be suitable.
At this time, in our institution, we perform both cardiac and
noncardiac analysis with large field-of-view in routine cardiac
MDCT. The primary purpose of noncardiac analysis is to differ-
entiate chest pain syndrome including aortic disease and pulmo-
nary embolism. In our study, noncardiac analysis could diagnose
the cause of chest symptom in 32 of 201 patients in whom
coronary artery disease was ruled out. In these patients, additional
diagnostic tests could be avoided and might result in reduced
medical costs.
Furthermore, as Dr. Rumberger pointed out in his editorial
comment (2), noncardiac analysis could be medico-morally
necessary. We believe that physicians should review all images
and areas irradiated in the cardiac scan. What is most needed at
the present time is for the cardiology community to adopt an
open mind so as to discuss this issue and to gather further input
from various fields.
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